We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.

Delisted

GBT was delisted on the 4th of October, 2022.

84 hedge funds and large institutions have $488M invested in Global Blood Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 19

26% more capital invested

Capital invested by funds: $389M → $488M (+$99.9M)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

10% less funds holding

Funds holding: 9384 (-9)

11% less call options, than puts

Call options by funds: $5.29M | Put options by funds: $5.97M

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

Holders
84
Holders Change
-9
Holders Change %
-9.68%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
15
Increased
38
Reduced
19
Closed
24
Calls
$5.29M
Puts
$5.97M
Net Calls
-$679K
Net Calls Change
-$1.33M
Name Holding Trade Value Shares
Change
Change in
Stake
Tudor Investment Corp
101
Tudor Investment Corp
Connecticut
-$435K -26,243 Closed
PIM
102
Partner Investment Management
California
-$338K -20,383 Closed
GCP
103
GSA Capital Partners
United Kingdom
-$181K -10,900 Closed
Simplex Trading
104
Simplex Trading
Illinois
-$114K -5,974 Closed
Teacher Retirement System of Texas
105
Teacher Retirement System of Texas
Texas
-$35K -2,128 Closed
TRCT
106
Tower Research Capital (TRC)
New York
-$22K -1,331 Closed
Parallax Volatility Advisers
107
Parallax Volatility Advisers
California
-$20K -1,200 Closed
Group One Trading
108
Group One Trading
Illinois
-$5.3K -278 Closed

GBT Hedge Fund Activity: Q3 2016 in Review

84 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2016, worth a combined $488M — up 26% from $389M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of GBT and 15 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 38 added.

The largest buyer was Wellington Management Group, adding an estimated $10.4M. The largest seller was Deerfield Management, cutting an estimated $29.8M.

  • 84 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2016, down from 93 in Q2 2016.
  • Funds reported $488M of Global Blood Therapeutics, Inc. stock for Q3 2016, up 26% quarter-over-quarter.
  • 15 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2016 and 24 closed out, a net change of -9 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q3 2016 was Wellington Management Group, an estimated $10.4M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q3 2016 was Deerfield Management, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2016.